TEG-20X

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTEG-20X

Drug Alias NameTCR gamma delta T-cell therapy (Gadeta)autologous T-cells expressing gamma delta T-cell receptor (Gadeta)TCR T-cell therapy (Gadeta)TEG-20X

ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionHuman leukocyte antigen modulators

TargetsHuman leukocyte antigen

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryNetherlands

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesGadeta BV

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGadeta BV

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A